Do analysts rate CPIX or LLY?

Eli Lilly and Company has a consensus target price of $1,230.89, suggesting a potential upside of 10.85%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eli Lilly and Company 1 Sell rating(s) 4 Hold rating(s) 23 Buy rating(s) 2 Strong Buy rating(s) 2.87

Does the media favor CPIX or LLY?

In the previous week, Eli Lilly and Company had 159 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 162 mentions for Eli Lilly and Company and 3 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 1.07 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eli Lilly and Company 111 Very Positive mention(s) 12 Positive mention(s) 24 Neutral mention(s) 8 Negative mention(s) 5 Very Negative mention(s) Positive

Do analysts recommend JNJ or CPIX?

Johnson & Johnson currently has a consensus price target of $253.04, suggesting a potential upside of 5.58%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities research analysts plainly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Johnson & Johnson 0 Sell rating(s) 7 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.74 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to JNJ or CPIX?

In the previous week, Johnson & Johnson had 101 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 104 mentions for Johnson & Johnson and 3 mentions for Cumberland Pharmaceuticals. Johnson & Johnson's average media sentiment score of 1.41 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 90 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CPIX or ABBV?

AbbVie has a consensus price target of $253.81, indicating a potential upside of 7.99%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AbbVie 0 Sell rating(s) 6 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.88

Does the media favor CPIX or ABBV?

In the previous week, AbbVie had 127 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 130 mentions for AbbVie and 3 mentions for Cumberland Pharmaceuticals. AbbVie's average media sentiment score of 1.01 beat Cumberland Pharmaceuticals' score of 0.00 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbbVie 83 Very Positive mention(s) 18 Positive mention(s) 25 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts recommend CPIX or MRK?

Merck & Co., Inc. has a consensus price target of $128.18, suggesting a potential upside of 7.07%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts clearly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Merck & Co., Inc. 0 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.68

Does the media favor CPIX or MRK?

In the previous week, Merck & Co., Inc. had 50 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 53 mentions for Merck & Co., Inc. and 3 mentions for Cumberland Pharmaceuticals. Merck & Co., Inc.'s average media sentiment score of 1.37 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merck & Co., Inc. 46 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Do analysts rate CPIX or PFE?

Pfizer has a consensus target price of $28.82, indicating a potential upside of 16.46%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pfizer 2 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.25

Does the media favor CPIX or PFE?

In the previous week, Pfizer had 80 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 83 mentions for Pfizer and 3 mentions for Cumberland Pharmaceuticals. Pfizer's average media sentiment score of 0.87 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 41 Very Positive mention(s) 12 Positive mention(s) 17 Neutral mention(s) 7 Negative mention(s) 6 Very Negative mention(s) Positive

Cumberland Pharmaceuticals (CPIX) Competitors

$5.83 +0.26 (+4.67%)

Closing price 04:00 PM Eastern

Extended Trading

$5.81 -0.02 (-0.27%)

As of 07:52 PM Eastern

Compare

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? MarketBeat compares Cumberland Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cumberland Pharmaceuticals include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Eli Lilly and Company has a consensus target price of $1,230.89, suggesting a potential upside of 10.85%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cumberland Pharmaceuticals has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Eli Lilly and Company has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.96	-$2.84M	-$0.49	N/A
Eli Lilly and Company	$65.18B	16.04	$20.64B	$28.15	39.44

Eli Lilly and Company has a net margin of 34.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Eli Lilly and Company's return on equity of 105.77% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Eli Lilly and Company	34.98%	105.77%	23.76%

In the previous week, Eli Lilly and Company had 159 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 162 mentions for Eli Lilly and Company and 3 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 1.07 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eli Lilly and Company	111 Very Positive mention(s)	12 Positive mention(s)	24 Neutral mention(s)	8 Negative mention(s)	5 Very Negative mention(s)	Positive

Summary

Eli Lilly and Company beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Johnson & Johnson currently has a consensus price target of $253.04, suggesting a potential upside of 5.58%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities research analysts plainly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Johnson & Johnson has a net margin of 21.83% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Johnson & Johnson's return on equity of 32.60% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

In the previous week, Johnson & Johnson had 101 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 104 mentions for Johnson & Johnson and 3 mentions for Cumberland Pharmaceuticals. Johnson & Johnson's average media sentiment score of 1.41 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	90 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Johnson & Johnson has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.12	$26.80B	$8.65	27.71
Cumberland Pharmaceuticals	$44.52M	1.96	-$2.84M	-$0.49	N/A

Summary

Johnson & Johnson beats Cumberland Pharmaceuticals on 15 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to AbbVie?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Cumberland Pharmaceuticals has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AbbVie has a consensus price target of $253.81, indicating a potential upside of 7.99%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

AbbVie has a net margin of 5.79% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Cumberland Pharmaceuticals' return on equity of -12.01% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
AbbVie	5.79%	-576.45%	13.39%

In the previous week, AbbVie had 127 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 130 mentions for AbbVie and 3 mentions for Cumberland Pharmaceuticals. AbbVie's average media sentiment score of 1.01 beat Cumberland Pharmaceuticals' score of 0.00 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbbVie	83 Very Positive mention(s)	18 Positive mention(s)	25 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

AbbVie has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.96	-$2.84M	-$0.49	N/A
AbbVie	$61.16B	6.79	$4.23B	$2.03	115.78

Summary

AbbVie beats Cumberland Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Merck & Co., Inc. has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.96	-$2.84M	-$0.49	N/A
Merck & Co., Inc.	$65.01B	4.55	$18.25B	$3.55	33.72

Merck & Co., Inc. has a consensus price target of $128.18, suggesting a potential upside of 7.07%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts clearly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68

In the previous week, Merck & Co., Inc. had 50 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 53 mentions for Merck & Co., Inc. and 3 mentions for Cumberland Pharmaceuticals. Merck & Co., Inc.'s average media sentiment score of 1.37 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merck & Co., Inc.	46 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Merck & Co., Inc. has a net margin of 13.59% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Merck & Co., Inc.'s return on equity of 27.55% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Merck & Co., Inc.	13.59%	27.55%	10.73%

Cumberland Pharmaceuticals has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Summary

Merck & Co., Inc. beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Pfizer?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Pfizer had 80 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 83 mentions for Pfizer and 3 mentions for Cumberland Pharmaceuticals. Pfizer's average media sentiment score of 0.87 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	41 Very Positive mention(s)	12 Positive mention(s)	17 Neutral mention(s)	7 Negative mention(s)	6 Very Negative mention(s)	Positive

Pfizer has a net margin of 11.83% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Pfizer's return on equity of 19.44% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Pfizer	11.83%	19.44%	8.41%

Pfizer has a consensus target price of $28.82, indicating a potential upside of 16.46%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pfizer has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.96	-$2.84M	-$0.49	N/A
Pfizer	$62.58B	2.25	$7.77B	$1.31	18.89

Cumberland Pharmaceuticals has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Summary

Pfizer beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPIX vs. The Competition

Export

Metric	Cumberland Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$83.46M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-11.90	12.70	21.07	22.20
Price / Sales	1.96	336.83	530.36	110.15
Price / Cash	15.19	56.31	44.82	54.51
Price / Book	3.55	4.11	10.79	6.50
Net Income	-$2.84M	$64.45M	$3.56B	$336.88M
7 Day Performance	2.82%	2.24%	1.67%	-0.22%
1 Month Performance	-0.68%	1.04%	0.43%	0.77%
1 Year Performance	48.35%	30.05%	32.84%	31.57%

Cumberland Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPIX Cumberland Pharmaceuticals	0.4786 of 5 stars	$5.83 +4.7%	N/A	+28.0%	$83.46M	$44.52M	N/A	80	News Coverage
LLY Eli Lilly and Company	4.6111 of 5 stars	$1,116.32 -0.6%	$1,227.74 +10.0%	+44.6%	$1.05T	$65.18B	39.63	50,000	Trending News Dividend Announcement Analyst Forecast
JNJ Johnson & Johnson	4.5672 of 5 stars	$232.45 -1.2%	$253.04 +8.9%	+54.3%	$558.45B	$94.19B	26.82	138,200	Trending News
ABBV AbbVie	4.7134 of 5 stars	$220.78 -0.8%	$253.43 +14.8%	+24.3%	$389.17B	$62.82B	108.51	57,000	Trending News Dividend Announcement Analyst Forecast
MRK Merck & Co., Inc.	4.4615 of 5 stars	$115.25 +0.1%	$128.18 +11.2%	+45.7%	$284.14B	$65.77B	32.41	75,000	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPIX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Do analysts rate CPIX or LLY?

Do institutionals & insiders hold more shares of CPIX or LLY?

Which has more volatility and risk, CPIX or LLY?

Which has preferable valuation and earnings, CPIX or LLY?

Is CPIX or LLY more profitable?

Does the media favor CPIX or LLY?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Do analysts recommend JNJ or CPIX?

Do insiders & institutionals hold more shares of JNJ or CPIX?

Is JNJ or CPIX more profitable?

Does the media refer more to JNJ or CPIX?

Which has more volatility and risk, JNJ or CPIX?

Which has higher valuation and earnings, JNJ or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Which has more volatility & risk, CPIX or ABBV?

Do insiders and institutionals believe in CPIX or ABBV?

Do analysts recommend CPIX or ABBV?

Is CPIX or ABBV more profitable?

Does the media favor CPIX or ABBV?

Which has higher earnings and valuation, CPIX or ABBV?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Do institutionals and insiders hold more shares of CPIX or MRK?

Which has stronger earnings and valuation, CPIX or MRK?

Do analysts recommend CPIX or MRK?

Does the media favor CPIX or MRK?

Is CPIX or MRK more profitable?

Which has more volatility and risk, CPIX or MRK?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Does the media favor CPIX or PFE?

Is CPIX or PFE more profitable?

Do analysts rate CPIX or PFE?

Do institutionals and insiders believe in CPIX or PFE?

Which has higher earnings & valuation, CPIX or PFE?

Which has more volatility & risk, CPIX or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools